U.S. Markets open in 7 hrs 7 mins

Rexahn Pharmaceuticals, Inc. (REXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8100-0.0200 (-1.09%)
At close: 4:00PM EST
Sign in to post a message.
  • A
    Andy
    I am hoping Rx & Abaraxin combo in Pancreatic in Ph. 2 will be BTD to save life... & Supinoxin will combo with Niv or/and with ipi as were studies... Peter..
  • A
    Andy
    And who is doing the clinical studies for Rx ....
  • B
    Boris
    How much do you think the value of the stock will be after the merger with Ocuphire Pharma.
  • A
    Andy
    I am here over 5 yrs 98% red & 2% last chance of honesty Richard Rogers on Board, hopefully the Ocup blindness leading the Rx deaf to the brighter future for sickness patients... Amen... thx
  • B
    Boris
    When to stop trading these shares.
  • f
    francis
    I just sold 30 of my shares that were once worth $3000, solely for tax write off. Probably do the same next year right after the 1st and hopefully before the merger!
  • E
    Ernie
    I'm really hoping : all pass, and current insiders ....... go to jail for a very long time.
  • A
    Andy
    Bio scam by the couSinn of Ahn & Peter! 3x R/S... goD & Jesuz are witnezz this E. PluriBusiness U2...Got Bless 2U..
  • A
    Andy
    Peter: U can running but can't hidden from the True... gooogle now used the Curry Beef recipe will facing ---> antiTRUST.... vs. E. Pluribus Unum... Π…
  • D
    Dejan
    News is great I’m in at 7.22 this should push to 12 today maybe even more. They are getting 226 mil. that’s almost 7x market cap.
  • J
    Jedi
    Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Given a $20.00 Price Target by HC Wainwright Analysts
  • G
    GS
    I have been a "bagholder" for 12+ years. REXN has two very interesting drugs in the pipeline RX-0201 and RX-0301. If you read the public contract with Zhejiang HaiChang Biotechnology it certainly appears to be a potential buyout. "milestone payments related to RX-0201 and RX-0301, up to $33M in milestones related to RX-0047, low-tens royalties on net sales of the first two and mid-single-digit royalties on net sales of RX-0047. It will also earn a portion of any sublicensing revenue." I am not an attorney but it sure sounds like a buyout. GLTA!
    Bullish
  • B
    Bigottimista
    Another big volume day. Price up 12%. Good to see. Wonder what's going on. No relevant news as far as I know. Any ideas?
  • L
    Lazerator
    2019 ASCO Gastrointestinal Cancers Symposium: Jan.17-19 in San Francisco, California.

    Clinical Trial Results ASCO-GI Presentations

    Rexahn Pharmaceuticals, Inc. (NYSE: RNN) will present updated Phase 2 data for its RX-3117, in combination with Abraxane, which is being evaluated as a first-line treatment for pancreatic cancer.
  • b
    biagio
    Rexan target prices set at $8.00 by ZACKS INVESTMENT.Looks good to me.
  • T
    Turk
    All this company is in business for is to draw capital out of the markets so the management can have a paycheck until the reach retirement age.
  • S
    S 4 BIO
    ASCO coming up soon:
    “Rexahn had a strong start to 2018, with the presentation of encouraging data on RX-3117 in metastatic pancreatic cancer and advanced bladder cancer and the announced collaboration with Haichang to develop RX-0201 for hepatocellular carcinoma,” said Peter D. Suzdak, Ph.D., chief executive officer of Rexahn. “We look forward to the continued clinical advancement of RX-3117 and RX-5902 and we will be presenting data on these programs in June at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. These data will include interim data from the Phase 2a trials of RX-3117 in advanced bladder cancer patients and of RX-5902 in patients with triple-negative breast cancer. We also look forward to presenting data later this year on the ongoing Phase 2a trial of RX-3117 in combination with Abraxane® in newly diagnosed metastatic pancreatic cancer patients.”
  • d
    daryl
    JAN HIGH $17 - so in 5 months FPOS down 70% THATS JUST THIS YEAR 2019 - AT THIS RATE WE WILL BE DOWN 90% BY THE END OF THE YEAR
  • J
    Jagda
    Get recent development, updates and product pipeline of the Rexahn Pharmaceuticals
    https://fintel.io/b/rnn-rexahn-pharmaceuticals-analysis-and-research-report-17510
    Fintel.io provides advanced investment research tools for finance professionals. Current coverage includes activist filings, institutional holdings, insider trading activity, and global headline news of over 60,000 companies worldwide.
    Fintel.io provides advanced investment research tools for finance professionals. Current coverage includes activist filings, institutional holdings, insider trading activity, and global headline news of over 60,000 companies worldwide.
    fintel.io
  • E
    Elvis
    The dormancy is over. Taken us all by surprise.